Switching from premixed insulin to basal-bolus insulin glargine plus rapid-acting insulin: The atlantic study

Acta Clinica Belgica

Volumn 68, Issue 1, 2013, Pages 28-33

  Mathieu, C ^a   Storms, F ^b   Tits, J ^c   Veneman, T F ^d   Colin, I M ^e  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b ST ANTONIUS HOSPITAL   (Netherlands)

^c DEPARTMENT OF CARDIOLOGY   (Belgium)

^d TWENTEBORG HOSPITAL   (Netherlands)

^e UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Basal bolus regimen; Insulin glargine; Premixed insulin

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN GLULISINE; ISOPHANE INSULIN; SHORT ACTING INSULIN; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLARGINE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LONG ACTING INSULIN;

ADULT; ARTICLE; BELGIUM; BODY MASS; BODY WEIGHT; CEREBROVASCULAR ACCIDENT; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEOPLASM; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PNEUMONIA; VOMITING; AGED; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG ADMINISTRATION; LONGITUDINAL STUDY; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; BELGIUM; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; INSULIN, SHORT-ACTING; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NETHERLANDS; PATIENT SATISFACTION; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84879536305     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.2143/ACB.68.1.2062716     Document Type: Article

References (16)

1. Cook MN, Girman CJ, Stein PP, Alexander CM. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. Diabet Med 2007; 24(4): 350-358
2. Heine RJ, Diamant M, Mbanya JC, Nathan DM. Management of hyperglycaemia in type 2 diabetes: The end of recurrent failure BMJ 2006; 333(7580): 1200-1204
3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359(15): 1577-1589
4. Nathan DM, Buse JB, Davidson MB, et al. American Diabetes Association; European Association for Study of Diabetes: Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32(1): 193-203
5. Davies M, Sinnassamy P, Storms F, Gomis R. Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies. Diabetes Res Clin Pract 2008; 79(2): 368-375
6. Fritsche A, Larbig M, Owens D, Haring HU. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study. Diabetes Obes Metab 2010; 12(2): 115-123
7. Sharplin P, Gordon J, Peters JR, Tetlow AP, Longman AJ, McEwan P. Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: A retrospective primary care-based analysis. Cardiovasc Diabetol 2009; 8:9
8. Riddle MC, Rosenstock J, Gerich J. Insulin Glargine 4002 Study Investigators. The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086
9. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC. 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 1716-1730
10. International Diabetes Federation. IDF Clinical Guidelines Task Force. Global guideline for Type 2 diabetes. Brussels: Brussels International Diabetes Federation; 2005
11. Hammer H, Klinge A. Patients with type 2 diabetes inadequately controlled on premixed insulin: Effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice. Int J Clin Pract 2007; 61(12): 2009-2018
12. Martorella AJ. Iatrogenic hypoglycemia in patients with type 2 diabetes: Comparison of insulin analog premixes and human insulin premixes. Postgrad Med 2011; 123: 7-16
13. Cramer JA, Pugh MJ. The influence of insulin use on glycemic control: How well do adults follow prescriptions for insulin Diabetes Care 2005; 28(1): 78-83
14. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: An analysis of third-party managed care claims data. Clin Ther 2006; 28(10): 1712-1725
15. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342(25): 1878-1886
16. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342(25): 1887-1892.